Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LGP Classic CBD
- Development stage
- Phase 4
- Lead developer
- Little Green Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LGP Classic CBD (also known as LGP Classic CBD 50) is a CBD-dominant medicinal cannabis oil developed by **Little Green Pharma (LGP)**, an Australian pharmaceutical company. The product is a whole-plant extract oral oil formulation containing 50 mg/mL of **cannabidiol (CBD)** as the active ingredient, with trace amounts of tetrahydrocannabinol (THC), dissolved in a medium-chain triglyceride (MCT) carrier oil. It is classified as a Schedule 4 medicine in Australia and has been evaluated in clinical trials for the management of cancer-related symptoms. The drug acts primarily through the endocannabinoid system, where CBD functions as a negative allosteric modulator of the **Cannabinoid receptor 1 (CB1)** and **Cannabinoid receptor 2 (CB2)**, as well as interacting with other non-cannabinoid targets like TRPV1 and GPR55.
- Brand names
- LGP Classic CBD
- Other names
- LGP Classic CBD 50:0LGP Classic CBD 50 medicinal cannabis oil
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)FAAHGPR55 (G protein-coupled receptor 55)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on LGP Classic CBD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LGP Classic CBD.